NASDAQ$RCKT
Rocket Pharmaceuticals Inc · Q3 2021 earnings
Q3 2021 earnings · · Investor relations
Briefing
Rocket Pharmaceuticals reported financial results for the quarter ending September 30, 2021, and provided updates on key pipeline developments.
Rocket Pharmaceuticals reported a net loss of $50.1 million for the third quarter of 2021. The company's cash, cash equivalents, and investments totaled $421.5 million as of September 30, 2021, which is expected to fund operations into the second half of 2023.
- Treatment initiated in pediatric patient cohort in Danon Disease trial of RP-A501
- Treatment completed in nine of nine patients in LAD-1 Phase 1/2 trial; favorable safety profile and initial clinical benefit reported in all seven patients with at least 3 months of follow up
- Clinical updates anticipated in Danon Disease at AHA 2021 Scientific Sessions and in FA, LAD-I and PKD at 63rd ASH Annual Meeting
- Ending Balance Sheet with $421.5 Million in Cash; Cash Runway Expected into 2H’23
Headline financials
Revenue & EPS history
Rocket · Revenue · Quarterly
$0
Forward guidance
Rocket expects its balance in cash, cash equivalents and investments of $421.5 million as of September 30, 2021 to fund its operations into the second half of 2023.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2021
+0.8%
Avg return
Earnings day
+0.3%
Avg return
5 days after
-1.9%
Avg return
30 days after
51%
23 / 45 earnings
Positive
+18.2%
Q1 2023
Best reaction
-17.7%
Q1 2016
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -3.4% | -6.0% | -29.0% | |
| Q4 2025 | +10.8% | +6.4% | -16.8% | |
| Q3 2025 | +0.3% | +2.2% | +2.8% | |
| Q1 2025 | -0.6% | +0.9% | -55.7% | |
| Q4 2024 | +0.5% | -2.0% | -19.3% | |
| Q3 2024 | -0.7% | -8.8% | -21.0% | |
| Q2 2024 | -3.6% | -8.8% | -14.5% | |
| Q1 2024 | -0.5% | -3.2% | -1.6% | |
| Q4 2023 | +5.0% | +4.3% | -6.9% | |
| Q3 2023 | -2.4% | -11.6% | +23.1% | |
| Q2 2023 | -2.6% | -4.2% | -7.8% | |
| Q1 2023 | +18.2% | +16.4% | +23.0% | |
| Q4 2022 | +5.9% | +14.8% | -7.7% | |
| Q3 2022 | -6.0% | -10.8% | +9.9% | |
| Q2 2022 | +4.3% | +12.3% | +1.5% | |
| Q1 2022 | -15.2% | -17.2% | +20.4% | |
| Q4 2021 | +4.3% | -2.6% | -11.4% | |
| Q3 2021 | +10.3% | +8.0% | -30.2% | |
| Q2 2021 | -4.9% | -13.9% | -1.8% | |
| Q1 2021 | -3.9% | -6.5% | +3.6% | |
| Q4 2020 | -0.7% | -1.8% | -16.9% | |
| Q3 2020 | +5.3% | +0.2% | +9.2% | |
| Q2 2020 | +6.3% | +10.6% | -8.1% | |
| Q1 2020 | -1.5% | +12.7% | +8.5% | |
| Q4 2019 | -1.1% | -7.7% | -30.3% | |
| Q3 2019 | +10.2% | +4.0% | +50.6% | |
| Q2 2019 | +4.5% | -3.2% | +0.4% | |
| Q1 2019 | +1.6% | -8.7% | -14.6% | |
| Q4 2018 | -4.7% | -2.1% | +27.4% | |
| Q3 2018 | -1.0% | -12.5% | -17.6% | |
| Q2 2018 | +3.8% | -5.3% | +9.0% | |
| Q1 2018 | +6.5% | +19.8% | +23.2% | |
| Q4 2017 | -0.4% | +0.2% | -19.2% | |
| Q3 2017 | +2.0% | +15.7% | +3.6% | |
| Q2 2017 | +8.3% | +16.7% | +13.3% | |
| Q1 2017 | -9.6% | +0.0% | -1.4% | |
| Q4 2016 | +8.7% | -4.3% | +24.6% | |
| Q3 2016 | +4.5% | +4.5% | +1.5% | |
| Q2 2016 | +0.1% | +2.7% | +1.8% | |
| Q1 2016 | -17.7% | — | — | |
| Q4 2015 | -3.3% | — | — | |
| Q3 2015 | -6.9% | — | — | |
| Q2 2015 | -4.1% | — | — | |
| Q1 2015 | +0.3% | — | — | |
| Q4 2014 | +7.9% | — | — | |
| Q3 2014 | — | — | — | |
| Q2 2014 | — | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro